Equity Components [Axis]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Sale of Stock [Axis]
At-The-Market Offering Agreement [Member]
Private Placement [Member]
Private Placement Offering One 2025 [Member]
Private Placement Offering Two 2025 [Member]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Warrant [Member]
Related and Nonrelated Parties [Axis]
FGMK LLC and FGMK Business Holdings, LLC [Member]
Statistical Measurement [Axis]
Minimum [Member]
FGMK Business Holdings, LLC [Member]
Stan Smith [Member]
Ramiro Guerrero [Member]
Measurement Frequency [Axis]
Fair Value, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Counterparty Name [Axis]
H.C. Wainwright & Co., LLC [Member]
Maximum [Member]
Confidentially Marketed Public Offering [Member]
Award Type [Axis]
Restricted Stock [Member]
IPO [Member]
Over-Allotment Option [Member]
Valuation Approach and Technique [Axis]
Black Sholes Method [Member]
Registered Direct Offering [Member]
Plan Name [Axis]
Amendment of Warrant Agreements [Member]
Title and Position [Axis]
Director [Member]
2021 Equity Incentive Plan [Member]
Affiliated and Nonaffiliated Investor [Member]
Non-affiliated Investors [Member]
2018 Stock Option Plan [Member]
Amended And Restated 2020 Equity Incentive Plan [Member]
Performance Shares [Member]
Vesting [Axis]
Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Payment Arrangement, Tranche Two [Member]
Ateganosine THIO Therapeutics Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Amended Patent and Technology License Agreement [Member]
University of Texas Southwestern [Member]
Concentration Risk Benchmark [Axis]
Net Sales Up to $1,000,000,000 [Member]
Net Sales Above $1,000,000,000 [Member]
Patent and Technology License Agreement [Member]
Regeneron Pharmaceuticals Inc [Member]
BeiGene Swizerland Gmb H [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Employees and Consultants [Member]
Master Services Agreement [Member]
Research and Development Services [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Listing, Par Value Per Share
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash
Prepaid expenses and other current assets
Total current assets
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Total current liabilities
Long term liabilities:
Warrant liability
Total liabilities
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value, 30,000,000 shares authorized at March 31, 2026 and December 31, 2025, 0 shares issued and outstanding
Common stock, $0.0001 par value, 150,000,000 shares authorized at March 31, 2026 and at December 31, 2025, respectively, 60,671,491 and 38,624,289 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Operating expenses:
Research and development expenses
General and administrative expenses
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Grant income
Change in fair value of warrant liability
Other income (expense) net:
Net loss
Net loss per share:
Basic
Diluted
Weighted average common shares outstanding - basic
Weighted average common shares outstanding - diluted
Net loss
Foreign currency translation adjustment
Comprehensive loss
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Exercise of stock options
Exercise of stock options, shares
Stock-based compensation expense
Issuance of restricted stock
Issuance of restricted stock, shares
Issuance of common shares in connection with the confidentially marketed public offering, net of $1,995,041 of issuance costs
Issuance of common shares in connection with the confidentially marketed public offering, net of $1,995,041 of issuance costs, shares
Net loss
Issuance of common shares in connection with At-The-Market financing, net of $130,220 of issuance costs
Issuance of common shares in connection with At-The-Market financing, net of $130,220 of issuance costs, shares
Issuance of common shares in connection with the Private Placement Offerings, net of $74,448 of issuance costs
Issuance of common shares in connection with the Private Placement Offerings, net of $74,448 of issuance costs, shares
Issuance of warrants in connection with the Private Placement Offerings
Balance
Balance, shares
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Stock issuance costs
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Restricted stock issued for consulting expense
Change in fair value of warrant liability
Change in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable
Accrued expenses
Net cash used in operating activities
Cash flows from financing activities:
Proceeds from exercise of stock options
Proceeds from private placement
Proceeds from confidentially marketed public offering
Proceeds from At-The-Market offering
Payment of offering transactions costs
Net cash provided by financing activities
Net effect of foreign currency exchange on cash
Net increase in cash
Cash at beginning of period
Cash at end of period
Supplemental disclosure of cash flow information:
Warrants issued in connection with private placement offering 1 2025
Warrants issued in connection with private placement offering 2 2025
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Rule 10b5-1 Arrangement Modified
Non-Rule 10b5-1 Arrangement Modified
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS
Payables and Accruals [Abstract]
ACCRUED EXPENSES
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL LIABILITIES
Equity [Abstract]
STOCKHOLDERS’ EQUITY
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Income Tax Disclosure [Abstract]
INCOME TAXES
Segment Reporting [Abstract]
SEGMENT INFORMATION
Government Assistance [Abstract]
GOVERNMENT GRANTS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Liquidity
Basis of Presentation and Consolidation Principles
Segment Information
Use of Estimates
Certain Risks and Uncertainties
Foreign Currency Translation
Off-Balance Sheet Risk and Concentrations of Credit Risk
Cash and Cash Equivalents
Fair Value Measurements
General and Administrative
Research and Development
Research and Development Incentive
National Institute of Health (NIH) Grant
Derivative Financial Instruments
Stock-Based Compensation
Common Stock Warrants
Income Taxes
Recent Accounting Standards
Net Loss Per Share
Leases
Recent Accounting Standards
SCHEDULE OF ANTIDILUTIVE SHARES EXCLUDED FROM CALCULATION OF DILUTIVE LOSS PER SHARE
SCHEDULE OF ACCRUED EXPENSES
SCHEDULE OF FAIR VALUE MEASUREMENT OF EMBEDDED DERIVATIVE LIABILITIES AND WARRANT LIABILITIES
SCHEDULE OF CHANGES IN FAIR VALUE OF THE DERIVATIVE LIABILITIES AND WARRANT LIABILITIES
SCHEDULE OF WARRANT ACTIVITY
SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS
SCHEDULE OF ACTIVITY AND INFORMATION OF OUTSTANDING AND EXERCISABLE OPTIONS
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS
SCHEDULE OF STOCK BASED COMPENSATION EXPENSE
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares issuable upon exercise of warrants
Entity incorporation, state or country code
Entity incorporation, date of incorporation
Working capital
Accumulated deficit
Current liabilities
Number of operating segments
Cash equivalents
Reimbursement of research and development expenses
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Percentage of stock owned
Accounting, tax and valuation services expense
Numbert of common stock issued
Warrants issued to purchase common stock
Aggregate purchase price
Bonus
Professional fees
Research and development costs
Other
Total accrued expenses
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities
Balance, beginning of period
Issuance of warrants
Exercise of warrants
Amendment of warrants
Gain on fair value of warrant liability
Balance, end of period
Warrants Outstanding, Beginning balance
Weighted Average Exercise Price, Beginning balance
Weighted Average Remaining Contractual Term in Years
Warrants, Issued
Weighted Average Exercise Price, Issued
Warrants, Exercised
Weighted Average Exercise Price, Exercised
Warrants, Expired
Weighted Average Exercise Price, Expired
Warrants Outstanding, Ending balance
Weighted Average Exercise Price, Ending balance
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Fair value assumptions, contractual term
Volatility rate
Expected dividend yield
Options Outstanding, Beginning balance
Weighted Average Exercise Price, Beginning balance
Weighted Average Remaining Contractual Term in Years, Outstanding
Aggregate Intrinsic Value, Beginning balance
Options, Granted
Weighted Average Exercise Price, Granted
Options, Exercised
Weighted Average Exercise Price, Exercised
Options, Cancelled/forfeited
Weighted Average Exercise Price, Cancelled/forfeited
Options Outstanding, Ending balance
Weighted Average Exercise Price, Ending balance
Aggregate Intrinsic Value, Ending balance
Options, Exercisable
Weighted Average Exercise Price, Exercisable
Weighted Average Remaining Contractual Term in Years, Exercisable
Aggregate Intrinsic Value, Exercisable
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule Of Stock Based Compensation Expense
General and administrative
Research and development
Total stock-based compensation
Aggregate offering price
Number of common stock sold
Common stock per share
Gross proceeds from offering
Commissions paid
Issuance costs
Net proceeds from offering
Warrants issued to purchase common stock
Gross proceeds from private placement
Warrants exercise price, per share
Warrants term
Warrants expiration date
Other issuance cost
Research and development expense
Options granted
Unvested restricted shares
Warrants and rights exercisable period
Warrants value
Risk free interest rate
Warrants exercised
Number of common stock sold
Increase in equity on exercise of warrant liability
Warrant liability classified instruments
Stock options outstanding
Common stock reserved for issuance
Percentage of increase in stock outstanding fully diluted
Options contractual term
Percentage of shares granted
Exercise price percentage
Weighted-average grant date fair value
Unrecognized compensation
Unrecognized compensation expense, recognized period
Weighted average exercise price
Options granted
Investment amount
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Term of agreement
Milestone payment
Combined milestone payment maximum
Payments due related to milestones
Rate of royalties on net sales
Percentage of royalty description
Income tax expense (benefit)
Number of reporting segment
Segment reporting CODM profit (loss) measure description
Grants receivable
Subsequent Event [Table]
Subsequent Event [Line Items]
Number of option issued
Weighted exercise price
Number of restricted shares of common stock issued
Value of restricted shares of common stock issued
Share price
Grant income.
Warrants issued in connection with private placement offering one 2025.
Warrants issued in connection with private placement offering two 2025.
Private Placement Offering One 2025 [Member]
Private Placement Offering Two 2025 [Member]
Liquidity [Policy Text Block]
Certain Risks And Uncertainties [Policy Text Block]
Research And Development Incentive [Policy Text Block]
Common Stock Warrants [Policy Text Block]
Working capital.
Recent Accounting Standards [Policy Text Block]
Percentage of stock owned.
Stan Smith [Member]
Ramiro Guerrero [Member]
Accrued research and development costs current.
Aggregate offering price under sales agreement.
H.C. Wainwright & Co., LLC [Member]
At The Market Offering Agreement [Member]
Sales agent commissions.
Black Sholes Method [Member]
Registered Direct Offering [Member]
Increase in equity on exercise of warrant liability.
Amendment of Warrant Agreements [Member]
2021 Equity Incentive Plan [Member]
Affiliated and Nonaffiliated Investor [Member]
Schedule Of Warrant Exercised [Table Text Block]
Schedule of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block]
2018 Stock Option Plan [Member]
Amended And Restated 2020 Equity Incentive Plan [Member]
Share based compensation arrangement by share based payment award fair value assumptions percentage of increase in stock outstanding fully diluted.
Share based compensation arrangement by share based payment award fair value assumptions exercise price percentage.
Share based compensation arrangement by share based payment award fair value assumptions percentage of shares granted.
Term of agreement.
Ateganosine THIO Therapeutics Inc [Member]
Amended Patent and Technology License Agreement [Member]
Milestone payment.
Combined milestone payments maximum.
Payments due related to milestones.
University of Texas Southwestern [Member]
Percentage of royalty payments on net sales.
Net Sales Up to $1,000,000,000 [Member]
Net Sales Above $1,000,000,000 [Member]
Patent and Technology License Agreement [Member]
Percentage of royalty payments on net sales description.
Regeneron Pharmaceuticals Inc [Member]
BeiGene Swizerland Gmb H [Member]
Allocated share based compensation expense general and administrative.
Allocated share based compensation expense research and development.
Stock issued during period value public offering.
Stock issued during period shares public offering.
Confidentially Marketed Public Offering [Member]
Restricted stock issued for consulting expense.
Modified Flag.
Modified Flag.
Reimbursement of research and development expenses.
FGMK LLC and FGMK Business Holdings, LLC [Member]
FGMK Business Holdings, LLC [Member]
Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments grants in period weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments exercises in period weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments expirations in period weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.
Class of warrant or right exercised.
Non-affiliated Investors [Member]
Employees and Consultants [Member]
Master Services Agreement [Member]
Research and Development Services [Member]
Assets, Current
Assets
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Other Nonoperating Income (Expense)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Shares, Outstanding
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect, Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
New Accounting Pronouncements, Policy [Policy Text Block]
Proceeds from Warrant Exercises
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Payment Arrangement, Expense
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period